ARTICLE SUMMARY:
More good clinical news for Edwards Lifesciences’ TAVR devices—this time in so-called intermediate-risk patients—is expected to provide additional tail-winds for this already rapidly expanding market, particularly in the US.
Clinical outcomes in lower-risk patients treated with Edwards Lifesciences Corp.’s next-generation Sapien 3 transcatheter aortic heart valve repair (TAVR) device were presented at the American College of Cardiology (ACC) annual meeting in March, and the solidly positive results are predicted to further accelerate growth in the robust TAVR market, particularly in the US, where uptake in lower-risk patients could reach unprecedented levels over the next five years.
